At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 249 enrolled
Drug / intervention
HCP1803-3 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating HCP1803-3, RLD2001-1, and 2 other interventions for Hypertension. Completed, enrolled 249 participants across 1 site.
Detailed Summary
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 compared to RLD2001-1 in patients with essential hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
Enrollment StartMar 2024
First PostedMay 2024
Primary CompletionDec 2024
TodayJul 2026
First PostedMay 31, 2024
Enrollment StartMar 25, 2024
Primary CompletionDec 2, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.1 years ago
Interventions
HCP1803-3drug
Take it once daily for 8 weeks orally.
RLD2001-1drug
Take it once daily for 8 weeks orally.
HPP2003-3drug
Placebo drug. Take it once daily for 8 weeks orally.
HPP2002-1drug
Placebo drug. Take it once daily for 8 weeks orally.